摘要
目的:分析现有的蛋白激酶抑制剂的结构特征,将联杂环(嘧啶联苯)确立为母核骨架的模型,围绕嘧啶联苯这个骨架,在该模型基础上设计并合成新型的类药性小分子。方法:采用拼合原理反复优化嘧啶联苯这个母环模型,得到一系列结构新颖的联杂环类化合物。采用噻唑蓝法对所合成的化合物进行体外抗肿瘤活性的初步测定。结果:试验结果显示该类联杂环化合物对肿瘤细胞的增长具有抑制作用。结论:通过采用确定中心药效团并对其衍生化的方法,发现了一系列以嘧啶联苯为中心药效团的新型抗肿瘤化合物。
Objective.. To establishing pharmacophore models by analyzing known inhibitors and allosteric conforma tion, design and synthesize a series of drug-like small molecule library. Methods:We synthesized some novel protein kinase inhibitors of the phenylpyrimidine core. Tested their inhibitory activity against HeLa cells in cell assays. Results: Preliminary re suits indicated that some of these phenylpyrimidine derivatives possess potent anti-proliferative activities,with IC50 data in the micromolar range. Conclusion:The drug like molecule library approach is an effective method for the identification of novel hetero-biatyl anti-tumor compounds.
出处
《海南医学院学报》
CAS
2015年第7期882-884,887,共4页
Journal of Hainan Medical University
基金
哈尔滨医科大学附属第一医院科研基金(2013Y09)~~
关键词
蛋白激酶
抑制剂
联杂环
抗癌
Protein kinase, Inhibitor , Hetero-biatyl, Anti-cancer